|
Session 96
Poster Abstracts
Responses to and Efficacy of ART in Children
Monday, 1-4 pm
Room: Hall A |
| 579 |
Relation between Viral Load and CD4 Percentage in Children on Non-suppressive HAART Regimens
Andrew Steenhoff*1,2, R Rutstein1, K Propert2, S Douglas2, K Gebo3, G Siberry3, A Gaur4, R Warford5, S Spector6, and R Gross2
1Children`s Hosp Philadelphia, PA, US; 2Univ of Pennsylvania, Philadelphia, US; 3Johns Hopkins Univ, Baltimore, MD, US; 4St Jude Children`s Res Hosp, Memphis, TN, US; 5St Luke`s Roosevelt Hosp Ctr, New York, NY, US; and 6Univ of California, San Diego, US |
| 580 |
Short-cycle Therapy in Adolescents following Continuous Therapy with Established Viral Suppression: The Effect on Viral Load Suppression
Bret Rudy*1, J Sleasman2, B Kapogiannis3, C Wilson4, J Bethel5, C Cunningham6, and the Adolescent Trials Network for HIV/AIDS Interventions 015 Study Team
1Children`s Hosp Philadelphia and Univ of Pennsylvania Sch of Med, US; 2Univ of South Florida Sch of Med, US; 3Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 4Univ of Alabama at Birmingham Sch of Med, US; 5Westat, Bethesda, MD, US; and 6Duke Univ Sch of Med, Durham, NC, US |
581
 |
PACTG Protocol 1021: A Phase I/II Study of a Once-daily Regimen of Emtricitabine, Didanosine, and Efavirenz in HIV-infected, Therapy-naïve Children and Adolescents
Mobeen Rathore*1, R McKinney2, C Hu3, P Britto3, M Smith4, L Serchuck5, L Draper6, A Horga7, G Chittick8, A Weinberg9, and P1021 Study Team
1Univ of Florida, Jacksonville, US; 2Duke Univ, Durham, NC, US; 3Harvard Univ, Boston, MA, US; 4NIH, Bethesda, MD, US; 5Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 6Frontier Sci and Tech Res Fndn, Amherst, NY, US; 7Bristol-Myers Squibb R&D, Wallingford, CT, US; 8Gilead Sci, Foster City CA, US; and 9Univ of Colorado Hlth Sci Ctr, Denver, US |
582
|
Treatment Responses to Atazanavir-containing HAART in a Drug-naïve Pediatric Population in South Africa
T Meyers1, R Rutstein2, P Samson3, A Violari1, Megan Palmer*1, J Kiser4, C Fletcher4, B Graham5, M Horga6, G Aldrovandi7, and PACTG 1020A Study Team
1Chris Hani Baragwanath Hosp, Johannesburg, South Africa; 2Children`s Hosp of Philadelphia, PA, US; 3Frontier Sci and Tech Res Fndn, Harvard Sch of Publ Hlth, Boston, MA, US; 4Univ of Colorado, Denver, US; 5Frontier Sci and Tech Res Fndn, Amherst, NY, US; 6Bristol-Myers Squibb, Wallingford, CT, US; and 7Children`s Hosp of Los Angeles, CA, US |
583
|
Early Effectiveness of a NVP-based HAART Regimen among HIV-infected Children with and without Prior Single-dose NVP Exposure
Linda Barlow-Mosha*, P Ajunua, M Mubiru, D Bagenda, M Luttajumwa, B Musoke, M Owor, and P Musoke
Makerere Univ Johns Hopkins Univ Res Collaboration, Kampala, Uganda |
584
|
Initial Growth, CD4, and Viral Load Responses to HAART in Ugandan Compared to UK/Irish HIV-infected Children
Addy Kekitiinwa*1, K Lee2, A Walker2, A Maganda1, K Doerholt2, H Lyall3, K Butler4, A Asiimwe1, M Kline1, and D Gibb2
1Baylor Coll of Med Children`s Fndn, Pediatric Infectious Disease Clin, Mulago Hosp, Uganda; 2Med Res Council Clinical Trials Unit, London, UK; 3St Mary`s Hosp, London, UK; and 4Our Lady`s Hosp for Sick Children, Dublin, Ireland |
585
|
Examination of HIV-1 Subtype and Response to ART in Ugandan Children
Addy Kekitiinwa*1, P Kasirye1, D Friedman2, E Coakley3, Y Lie3, and F Graziano2
1Mulago Hosp, Kampala Uganda; 2Univ of Wisconsin Hosp and Clin, Madison, US; and 3Monogram Biosci, South San Francisco, CA, US |
586
|
Efficacy and Safety of Double-boosted SQV/LPV/r Combination at 96 Weeks in Thai Children Who Have Failed NRTI/NNRTI-based Regimens
Torsak Bunupuradah*1, P Kosalaraksa2, C Engchanil2, P Boonrak1, T Hirunyanulux1, S Ubolyam1, P Lumbiganon2, K Ruxrungtham1,3, E Labriola-Tompkins4, J Ananworanich1,5, and HIV-NAT 017 Study Team
1HIV Netherlands Australia Thailand Res Collaboration, Bangkok; 2Khon Kaen Univ, Thailand; 3Chulalongkorn Univ, Bangkok, Thailand; 4Roche, Nutley, NJ, US; and 5South East Asia Res Collaboration with Univ of Hawaii, Bangkok, Thailand |
|
